On June 10, 2025 Nantes-based biotech XENOTHERA reported the value of its LIS22 antibody in the treatment of peripheral T-cell lymphomas (PTCL). The PALT1 clinical trial (NCT06495723) has just passed a new milestone at the trial’s scientific committee meeting, confirming continued recruitment (Press release, Xenothera, JUN 10, 2025, View Source [SID1234654024]). Clinical and biological safety, as well as injection tolerance, are encouraging. Preliminary efficacy data, yet to be confirmed, are very encouraging.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
To date, 9 patients are participating in the trial. No DLT has been observed, so enrolment at the 6 mg/kg dose is continuing. PALT1 is a Phase I/II trial testing the safety and efficacy of LIS22 in patients with refractory relapsed PTCL. The trial is taking place in France and Italy, with Professor Gandhi Damaj at Caen University Hospital as principal investigator.
The results will be presented orally on Tuesday June 18 at 5:50 p.m. by Firas Bassissi, the biotech’s Scientific Director, at the World Congress on Lymphoma (18th International Conference on Malignant Lymphoma, Lugano, Switzerland, View Source), during the "Experimental Medicines" session under the title "LIS22: An Effective Multimodal Polyclonal Antibody targeting T-Cell Malignancies".
In addition, the PALT1 clinical trial is the subject of an abstract to be published in the proceedings of the same congress (abstract 847: "PALT trial: First in class glyco humanized polyclonal antibody directed against tumoral T cells, in patients with relapsed/refractory peripheral T cells lymphoma (PTCL)").
"To be able to present LIS22 orally and to benefit from an abstract published in the proceedings of the Lugano World Congress is an immense source of pride, and confirms the interest of our treatment, as well as the recognition by the medical and scientific community of the quality and potential of our therapeutic antibody. I am of course delighted to be able to continue this trial, thanks to these results, which are both a validation of our approach and, above all, a source of hope for PTCL patients who have reached a therapeutic impasse. I would like to congratulate the XENOTHERA teams, and above all to thank the patients and medical teams who are working alongside us to analyze the therapeutic potential of LIS22," says Odile Duvaux, President of the biotech company.